Hangzhou Tianlong Biotechnology

Tianlong Science and Technology is a leading Chinese biotechnology company specializing in the development and manufacture of molecular diagnostic instruments and reagents. Founded in 1997, the company has established itself as a major player in the in vitro diagnostics (IVD) market, offering a comprehensive suite of products including automated nucleic acid extractors, real-time PCR systems, and over 300 types of diagnostic kits. Headquartered in Xi'an with a significant R&D and manufacturing hub in Hangzhou, Tianlong's technology is widely utilized in clinical diagnostics, infectious disease control, food safety, and forensic identification. The company gained international prominence for its critical role in the global response to the COVID-19 pandemic and is currently a subsidiary of Shanghai Kehua Bio-Engineering (KHB), following a high-profile acquisition and subsequent legal dispute over valuation.